Aeglea Revives Fortunes By Joining Merck And Roivant In TL1A Drug Chase

Spyre Buyout Brings Potential Long-Acting Rivals To IBD Drugs

Aeglea looked to be company running out of time, but the reverse merger with Spyre Therapeutics and its TL1A-based inflammatory bowel disease assets could prove to be an inspired move.

Aeglea Therapeutics

Micro-cap biotech Aeglea BioTherapeutics has impressed investors with a rapid pivot into the field of autoimmune disease, with the acquisition of Spyre Therapeutics.

Rare disease drug developer Aeglea has been in danger of going bust after its lead candidate, pegtarviliase, a treatment for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip